Globe Life's Buyback Bridge: Evri's Claims Shock Meets a 2027 EPS Guide Built on Repurchases
A startup health plan just turned a stable supplemental insurer's health margin negative; the 2027 plan leans harder on Bermuda cash and buybacks than underwriting.
GL · Earnings Call · 2026-10-22
Globe Life's Buyback Bridge: Evri's Claims Shock Meets a 2027 EPS Guide Built on Repurchases
The quarter that broke the health margin
Globe Life reported a messy third quarter: net income of $361 million, or $4.62 per share, down 2% year over year, while net operating income of $379 million, or $4.84, rose just 1%. More important, management cut 2026 operating EPS guidance to $15.35-$15.65 and introduced 2027 guidance of $16.10-$17.10, up 7% at the midpoint. The stock has been flat over the last 90 trading days and sits 9.5% below its August peak, so the market is not panicking — but it is clearly waiting to see whether this is noise or a new pattern.
The noise is health. Health premium revenue grew 16% to $447 million, yet health underwriting margin swung to negative $6 million from a positive $16 million a year ago. Frank Svoboda pinned it on two items: “underwriting results this quarter at United American General Agency Division were adversely impacted by a process change at CMS ... and high severity claims at Evri” — Frank Martin Svoboda, Co-Chief Executive Officer · 2026-10-22. The CMS Medicare ID reissuance issue added nearly $7 million of out-of-period Medicare Supplement claims, while Evri, the developing group health business inside United American, produced an underwriting loss of nearly $16 million. These are company-specific problems — the fresh high severity claims language and severity claim discussion are new to Globe Life's keyword profile and are not simply a sector-wide higher claims costs story. For GL, this is a startup health plan with lumpy claims, not a broad-based deterioration in supplemental health.
What changed: Evri went from '2% drag' to a credibility test
The most damaging part is the contrast with the prior call. In July, CFO Tom Kalmbach described Evri's first-half underwriting loss as roughly $10 million, with only $7 million in the second quarter, and said: “we only anticipate 3 million or $4 million in the second half of the year. So we do not anticipate the drag for the full year ... it might be about 2%” — Thomas Peter Kalmbach, Chief Financial Officer · 2026-07-23. One quarter later, Evri lost nearly $16 million in Q3 alone. That is a dramatic miss against the company's own near-term framing, and it explains why 2026 guidance came down.
Management is now explicit that the runway is longer. Matt Darden said the business is still tiny — only about $11 million of Q3 premium, roughly 30 groups today, maybe 50 next year, and around $100 million of annualized premium in 2027 — but high-severity claims can be over $100,000 each, and with a small number of groups those claims overwhelm the earned premium. The company has tightened underwriting, declining to quote more than 70% of cases, and can reprice or non-renew groups. Still, Kalmbach's guidance for 2027 now includes a possibility of further losses:
we do anticipate ... there is the possibility that there is still could be some level of losses in 2027 and built that into the overall range
That is why the 2027 health underwriting margin guide widened to 20%-24%, and why Q4 health margin is now expected at 20%-22% rather than the prior 23%-25% framing. The CMS issue should normalize, but the extra claims feed into claim trend and therefore into rate filing catch-up in the second quarter of 2027. The health segment is not broken, but it has become less predictable.
The buyback bridge is doing more of the lifting
The more important story for the stock is not Evri itself; it is what Globe Life's 2027 EPS guide reveals about the growth mix. Frank Svoboda was unusually direct: “probably in that range of 5% to 6%, probably coming from share buybacks. Is what we are anticipating, and then you are having a debt underwriting growth in net underwriting excuse me, net operating income more in that 1% to 2% range” — Frank Martin Svoboda, Co-Chief Executive Officer · 2026-10-22. In other words, roughly 5-6 points of the 7% EPS growth is capital return, and only 1-2 points is operating earnings. That is a different quality of growth than the mortality-driven reserve releases of recent years.
The fuel is real. Globe Life raised its 2026 buyback guide to $725-$775 million, about 70% of net operating income at the midpoint, and expects 2027 parent excess cash flow of $850-$950 million. The company also received reciprocal jurisdiction approval for its Bermuda subsidiary, Globe Life Re, and intends to request a dividend distribution from Bermuda — roughly $150 million combined for 2026-2027 — while keeping the U.S. subsidiaries within its targeted capital level range. The balance sheet supports it: repurchases of common stock reached $275 million in the latest quarter, up 10% year over year, and effective net cash was $14.9 billion. At 13.6x price to net income, the stock is not expensive, so buybacks are a rational use of capital.
But there is a catch: 2027 net investment income growth is guided to 2.5%-3.5%, while required interest grows 3.5%-4.0%. Excess investment income is therefore expected to be flat to slightly down, because assets are being distributed out of the insurance entities and returned to shareholders. The buyback bridge works, but it is increasingly a financial-engineering bridge rather than an underwriting-growth bridge.
Core franchise: productivity yes, distribution transition no
Underneath the health noise, the core agency story is mixed but improving. American Income life premium rose 4% to $470 million, underwriting margin rose 3%, and net life sales were flat as a 7% decline in agent count was offset by 11% higher productivity. Management has stabilized agent count with compensation changes and plans further structural changes late this year; it expects mid- to high-single-digit sales growth in 2027. Liberty National was stronger — agent count up 9%, life sales up 7% — while Family Heritage grew health sales 5% on 1% agent growth. The productivity gains are real, but they are offsetting rather than replacing recruiting weakness.
The weaker spot is Direct to Consumer, where life premium fell 1% and net life sales fell 12%. The cause is the same digital-advertising transition management has been discussing for several quarters: “AI powered search and consumer behavior, are impacting digital marketing for all goods and services including life insurance” — James Matthew Darden, Co-Chief Executive Officer · 2026-10-22. This is not new. On the prior call, Matt Darden already described “the quantity of search going down. And the volume of paid search” — James Matthew Darden, Co-Chief Executive Officer · 2026-07-23, and the current call adds little beyond saying inquiry rates improved late in Q3 with AI-enabled advertising. The AI search and paid search headwinds are now a recurring theme, not a one-quarter excuse. DTC still matters as a lead feeder — management expects 1 million leads this year — but it is unlikely to return to growth quickly.
Mortality tailwind is normalizing
Finally, the old earnings tailwind is fading. The annual assumption update reduced policy obligations by about $120 million this quarter, down from $131 million a year ago, and life underwriting margin was $458 million, down 5% on fluctuations in LTD assumption updates. Normalized life margin was 41.8%, up slightly from 41.5%. The company still expects remeasurement gains, but the 2027 guide assumes some assumption change benefit that is likely smaller than in 2026. In prior calls, favorable mortality and reserve releases were a meaningful part of the EPS story; now they are a diminishing support beam.
The takeaway
Globe Life is not in crisis. It has a strong core supplemental franchise, a cheap multiple, a large buyback, and a new Bermuda cash channel. But the third quarter exposed a company-specific execution risk in Evri that is bigger than management expected, and the 2027 EPS guide depends heavily on buybacks and Bermuda dividends while core net operating income grows only 1%-2%. If Evri losses persist into 2028, or if DTC's AI-search transition lasts longer than expected, the buyback bridge may support the stock but not re-rate it. The flat tape says investors are waiting for proof — and the burden is now on management to show that Evri is a contained startup issue rather than the first crack in a previously predictable underwriting story.